Sara Sampietro/LinkedIn
Nov 26, 2025, 10:32
Sara Sampietro Introduces The New HemosIL Chromogenic Factor IX
Sara Sampietro, Product Manager – EEMEA at Werfen, shared on LinkedIn:
”Last week in Nyborg, Denmark, I had the privilege to discuss the role of the laboratory in the management of patients with Hemophilia and introduce our latest release: the NEW HemosIL Chromogenic Factor IX.
A big thanks to our partner ILS and to everyone who joined the conversation and contributed to driving progress in Hemostasis care.
Together, we can continue to make a difference!”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch